Shots:

• The EC has granted ODD to Motixafortide (BL-8040) for the treatment of pancreatic cancer following the positive COMP’s opinion
• The ODD designation is based on initial data of ongoing P-IIa COMBAT/KEYNOTE-202 study assessing the combination of BL-8040 + Keytruda (pembrolizumab) + CT in patients with m-pancreatic cancer
• Motixafortide is a selective inhibitor of the CXCR4 chemokine receptor- currently being developed for multiple indications including mobilization of HSCs for autologous and allogeneic transplantations and treatment of solid tumors and hematological malignancies

Click here to­ read full press release/ article | Ref: BioLineRx | Image: The Pharma Letter